# Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma

> **NCT03961867** · PHASE3 · UNKNOWN · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 440 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03961867
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-15
- **Primary completion:** 2022-09
- **Final completion:** 2025-09
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961867, "Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03961867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*